

EMA/233158/2020

European Medicines Agency decision

P/0195/2020

of 15 May 2020

on the agreement of a paediatric investigation plan and on the granting of a waiver for spesolimab (EMEA-002475-PIP02-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0195/2020

of 15 May 2020

on the agreement of a paediatric investigation plan and on the granting of a waiver for spesolimab (EMA-002475-PIP02-19) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Boehringer Ingelheim International GmbH on 20 December 2019 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 March 2020, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for spesolimab, solution for infusion, solution for injection, intravenous use, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for spesolimab, solution for infusion, solution for injection, intravenous use, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216 - Ingelheim am Rhein, Germany.

EMA/PDCO/144683/2020
Amsterdam, 27 March 2020

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA-002475-PIP02-19

Scope of the application

Active substance(s):

Spesolimab

Condition(s):

Treatment of generalised pustular psoriasis

Prevention of generalised pustular psoriasis

Pharmaceutical form(s):

Solution for infusion

Solution for injection

Route(s) of administration:

Intravenous use

Subcutaneous use

Name/corporate name of the PIP applicant:

Boehringer Ingelheim International GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Boehringer Ingelheim International GmbH submitted for agreement to the European Medicines Agency on 20 December 2019 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 28 January 2020.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of generalised pustular psoriasis

The waiver applies to:

- the paediatric population from birth to less than 12 years;
- solution for infusion, solution for injection; intravenous use, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

1.2. Condition:

Prevention of generalised pustular psoriasis

The waiver applies to:

- the paediatric population from birth to less than 12 years;
- solution for infusion, solution for injection; intravenous use, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of generalised pustular psoriasis

2.1.1. Indication(s) targeted by the PIP

Treatment of acute or chronic Generalized Pustular Psoriasis (GPP) and prevention of flares.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for infusion

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	1	Study 1 (1368-0027) Randomized, parallel group, double blind, placebo controlled, dose-finding study to evaluate efficacy and safety of spesolimab compared to placebo in adolescents from 12 years to less than 18 years of age (and adults) with generalised pustular psoriasis.
Extrapolation, modelling and simulation studies	2	Study 2 Dose finding population PK study Study 3 Dose finding population PK/PD model
Other studies	0	Not applicable
Other measures	0	Not applicable.

2.2. Condition:

Prevention of generalised pustular psoriasis

2.2.1. Indication(s) targeted by the PIP

Treatment of acute or chronic Generalized Pustular Psoriasis (GPP) and prevention of flares.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 12 years to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Solution for infusion,

Solution for injection

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	1	Study 1 <i>as for condition treatment of generalised pustular psoriasis</i>
Extrapolation, modelling and simulation studies	2	Study 2 <i>as for condition treatment of generalised pustular psoriasis</i> Study 3 <i>as for condition treatment of generalised pustular psoriasis</i>
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	Before submission of the marketing authorisation application for the conditions treatment and prevention of generalised pustular psoriasis
Deferral for one or more measures contained in the paediatric investigation plan:	No